Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

• Larimar said the submission follows a multidisciplinary Type B pre-BLA meeting in which the FDA said the company's existing data package appears capable of supporting a BLA for accelerated approval.
• The company expects to submit the remaining modules in the second half of 2026.
• Larimar also said the FDA reaffirmed its willingness to consider frataxin as a novel surrogate endpoint for accelerated approval.

Larimar Therapeutics Inc. (LRMR) on Monday moved a step closer to seeking U.S. approval for its experimental Friedreich's ataxia treatment, nomlabofusp, after submitting the first module of a rolling biologics license application (BLA) to the U.S. Food and Drug Administration (FDA).

The clinical-stage biotech company also reported positive long-term open-label data, noting that patients treated with nomlabofusp continued to show sustained increases in frataxin levels, alongside directional improvements across multiple clinical outcome measures, after one year of treatment.

Larimar shares were down nearly 20% in Monday’s pre-market trade.

Why The FDA Milestone Matters For LRMR

Larimar said the submission follows a multidisciplinary Type B pre-BLA meeting in which the FDA said the company's existing data package appears capable of supporting a BLA for accelerated approval.

The company expects to submit the remaining modules in the second half of 2026.

Larimar also said the FDA reaffirmed its willingness to consider frataxin (FXN) as a novel surrogate endpoint for accelerated approval and indicated the company's exposure-response analysis, along with exploratory gene expression and lipid biomarker data, could help support the application.

The company said any approval would ultimately be subject to the FDA's review.

If approved, Larimar said it is targeting a commercial launch in mid-2027 while preparing to dose the first patient in its global confirmatory Phase 3 study in the third quarter of 2026.

What LRMR’s Latest Data Show

Larimar said patients receiving nomlabofusp continued to show sustained increases in skin frataxin levels, a protein deficient in people with Friedreich's ataxia.

At the one-year mark, all nine evaluable participants achieved frataxin levels above 50% of the average seen in healthy volunteers.

The company also reported directional improvements across multiple clinical measures compared with a natural history reference population.

Among participants who completed one year of treatment, one patient who was non-ambulatory at the start of the study became ambulatory, while none of the ambulatory patients progressed to non-ambulatory status.

Larimar said long-term treatment was generally well tolerated. The most common adverse events were mild-to-moderate injection-site reactions, while anaphylaxis occurred in 10 of 43 participants, with nine of those patients having previously received nomlabofusp in an earlier study.

What Is Friedreich's Ataxia?

Friedreich's ataxia is a rare, progressive genetic disorder that affects the nervous system and can impair movement, speech, and heart function. Larimar said there are currently no approved disease-modifying therapies that address the disease's underlying cause.

Nomlabofusp is designed to increase frataxin, a protein deficient in people with Friedreich's ataxia. The company is seeking accelerated approval based on frataxin levels as a potential surrogate endpoint.

Friedrich’s ataxia is estimated to affect 1 in 40,000 people worldwide.

What Retail Investors Think Of LRMR Stock

Retail sentiment on Stocktwits around Larimar trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.

LRMR stock is down 4% year-to-date, but up 19% over the past 12 months. The iShares Biotechnology ETF (IBB) is up 48% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 39%.

Also See: Dan Ives Says MSFT, ORCL Are 'Way Oversold', Expects A Reversal In Next 6-9 Months

For updates and corrections, email newsroom[at]stocktwits[dot]com.